IGHE and asthma: Its approval has provided a new therapeutic opportunity for asthma patients, encompassing both treatment-naïve individuals and those who have not achieved satisfactory outcomes with omalizumab or who have experienced adverse effects from anti-IgE agents due to their proven mechanism on the allergic inflammation pathway [18,23].